From the other side of the consultation, briefly. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.
GenomicsKate said:It is worth asking what the claim would look like if it were false.
This matches mine closely enough to be worth saying so out loud.
GenomicsKate said:It is worth asking what the claim would look like if it were false.
Adding the part of the answer the thread has not reached. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.
Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Happy to go further on any of that.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdding the numbers, since they settle part of this. For anyone assembling their own picture: Tmax is one to three days, terminal half-life about 165 to 170 hours, steady state at four to five weeks, and subcutaneous bioavailability near 89%. Those four numbers explain most of the questions people ask about timing.
A narrower follow-up, since the general answer is now clear:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?